Comparative proteomics analysis of human osteosarcomas and benign tumors of bone

AIM: To analyze the proteomic components of the tissue from human osteosarcoma and benign tumor of bone, and to search the diagnostic markers of osteosarcoma. METHODS: Five samples of osteosarcoma and 5 additive samples from benign bone tumor were analyzed by a series of methods including immobilized pH gradient two-dimensional polyacrylamide gel electrophoresis (2DE), deep purple staining. The ImageMaster 2DE analysis-software, as well as peptide mass fingerprint based on matrix-assisted laser desorption/ionization time of flying mass spectrometry (MALDI-TOF-MS) and SWISS-PROT database searching were used for data processing. RESULTS: The average spots in osteosarcoma and the benign tumor of bone were 1 386±101 and 1 270±202, respectively. 22 peptide mass fingerprint (PMF) maps were obtained by MOLDI-TOF-MS and identified by searching the SWISS-PROT database. Compared with those in benign tumor of bone, 15 proteins were significantly up-regulated, especially zinc finger protein 133 (Znf133), lamin B and tailless complex polypeptide 1 (TCP-1). 7 down-regulated proteins were observed, with the absence of protein kinase C inhibitor protein 1 (KCIP-1) in osteosarcoma. CONCLUSION: The results suggest that an obviously differential proteomic expression exists between the osteosarcoma and benign tumor of bone. The overexpression of Znf133, lamin B, TCP1 and low-expression of KCIP-1 may play an important role in the development of osteosarcoma, and may serve as diagnostic markers/therapeutic targets of osteosarcoma.